| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd43e12353298376fd7642260c1dbca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| filingDate |
2014-01-10^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-08-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9476863b27eff0b5fea26d33b710321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77569636b773f93dd5c0233a1dd45c11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdf56b18c7926fd16ea2c317297250d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a49dc9bdfcf6b4b465dbb431cf9cedb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f0c55bca153bfc5170918326b07fdd |
| publicationDate |
2016-08-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9402909-B2 |
| titleOfInvention |
Pharmaceutical dosage form comprising polymeric carrier composition |
| abstract |
A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2785677-C1 |
| priorityDate |
2008-06-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |